Search results for "trials"

showing 10 items of 966 documents

Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.

2021

Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention has developed into its own subspecialty of interventional cardiology. Dedicated terminology, techniques, devices, courses, and training programs have enabled progressive advancements. However, only a few randomized trials have been performed to evaluate the safety and efficacy of CTO percutaneous coronary intervention. Moreover, several published observational studies have shown conflicting data. Part of the paucity of clinical data stems from the fact that prior studies have been suboptimally designed and performed. The absence of standardized end points and the discrepancy in definitions also prevent…

Malemedicine.medical_specialtyClinical trial protocols as topicmedicine.medical_treatmentPsychological intervention030204 cardiovascular system & hematologySubspecialtylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawPhysiology (medical)MedicineHumansMedical physics030212 general & internal medicineCoronary VesselClinical Trials as TopicInterventional cardiologybusiness.industryClinical study designPercutaneous coronary interventionCoronary VesselsCoronary OcclusionCoronary occlusionEndpoint determination:Myocardial revascularizationObservational studyFemaleCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Is Overall Mortality the Right Composite Endpoint in Clinical Trials of Acute Respiratory Distress Syndrome?

2018

Objectives Overall mortality in patients with acute respiratory distress syndrome is a composite endpoint because it includes death from multiple causes. In most acute respiratory distress syndrome trials, it is unknown whether reported deaths are due to acute respiratory distress syndrome or the underlying disease, unrelated to the specific intervention tested. We investigated the causes of death after contracting acute respiratory distress syndrome in a large cohort. Design A secondary analysis from three prospective, multicenter, observational studies. Setting A network of multidisciplinary ICUs. Patients We studied 778 patients with moderate-to-severe acute respiratory distress syndrome…

Malemedicine.medical_specialtyCritical Care and Intensive Care MedicineHypoxemia03 medical and health sciences0302 clinical medicineInternal medicineCause of DeathmedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyCause of deathRandomized Controlled Trials as TopicRespiratory Distress SyndromeLungbusiness.industryMiddle AgedClinical trialmedicine.anatomical_structure030228 respiratory systemRelative riskCohortBreathingmedicine.symptombusinessCritical care medicine
researchProduct

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

2011

We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). Patients with active CLL were randomized to ofatumumab 500 mg (n = 31) or 1000 mg (n = 30) day 1, with fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 days 2-4, course 1; days 1-3, courses 2-6; every 4 weeks for 6 courses. The first ofatumumab dose was 300 mg for both cohorts. The median age was 56 years; 13% of patients had a 17p deletion; 64% had β2-microglobulin > 3.5 mg/L. Based on the 1996 National Cancer Institute Working Group (NCI-WG) guidelines, the complete respo…

Malemedicine.medical_specialtyCyclophosphamideClinical Trials and ObservationsChronic lymphocytic leukemiaImmunologyMedizinNeutropeniaOfatumumabAntibodies Monoclonal HumanizedBiochemistryGastroenterologychemistry.chemical_compoundChemoimmunotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideCD20Chlorambucilbiologybusiness.industryAntibodies MonoclonalCell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellNeoadjuvant TherapySurgeryFludarabineTreatment Outcomechemistrybiology.proteinFemaleImmunotherapybusinessVidarabinemedicine.drug
researchProduct

Epidemiology, prevention and screening for prostate cancer.

1996

Prostate cancer is a growing social problem. The economical impact is high and is likely to become greater in future years, not only because the number of patients diagnosed with prostatic neoplasias is increasing steadily, but also because of the promotion of screening programmes and the rise in the number of surgical procedures available. It can be concluded that, at the present stage, widespread implementation of screening cannot be recommended. The answer to the question of screening can only be provided by large randomised trials, comparing either screening versus no screening, or early versus delayed treatment in patients in whom early cancer is detected by screening.

Malemedicine.medical_specialtyEarly cancerUrologyCost-Benefit AnalysisRisk AssessmentProstate cancerEpidemiologymedicineHumansMass ScreeningIn patientStage (cooking)Intensive care medicineRandomized Controlled Trials as TopicPalpationbusiness.industryRectumProstatic NeoplasmsDelayed treatmentSurgical proceduresMiddle AgedProstate-Specific Antigenmedicine.diseasePrimary PreventionPhysical therapybusinessEuropean urology
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct

Management of pre-malignant and malignant lesions by endoscopic resection

2003

Endoscopic resection (ER) has gained more and more importance in the treatment of early gastrointestinal neoplasia over the last few years. The choice of the different available techniques depends on the site, the macroscopic type of the tumour and the personal experience of the endoscopist. The 'suck-and-cut' technique with ligation device or cap should be favoured to normal strip biopsy in the oesophagus because of the size of the resected specimen and its technical feasibility. A recently described method of ER in the stomach is the circumferential mucosal incision with a type of needle-knife and subsequent en-bloc resection following prior injection under the lesions. ER of high-grade i…

Malemedicine.medical_specialtyEsophageal NeoplasmsColorectal cancerEndoscopic mucosal resectionRisk AssessmentBarrett EsophagusStomach NeoplasmsmedicineHumansMinimally Invasive Surgical ProceduresGastrointestinal NeoplasmsNeoplasm StagingClinical Trials as TopicIntraepithelial neoplasiamedicine.diagnostic_testbusiness.industryStomachBiopsy NeedleGastroenterologyEndoscopymedicine.diseaseImmunohistochemistrydigestive system diseasesEndoscopySurgeryMajor duodenal papillaTreatment Outcomemedicine.anatomical_structureAdenocarcinomaFemaleLigationbusinessPrecancerous ConditionsFollow-Up StudiesBest Practice & Research Clinical Gastroenterology
researchProduct

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered sep…

2003

The safety and reactogenicity of a booster dose of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (N=4725) was compared with the separate administration of GSK Biologicals' DTPa-IPV/Hib and HBV vaccines (N=4474) in two open, randomized multicenter studies (A and B). Solicited symptoms occurring within 4 days of vaccination were recorded on diary cards and serious adverse events (SAEs) were collected throughout the study period. In Study A (N=1149), incidences of solicited symptoms were similar in both groups; there were no SAEs either reported within 4 days of vaccination or considered to be causally related to vaccination. In study B (N=8050), where fever was the only solicited sympt…

Malemedicine.medical_specialtyFeverImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesInternal medicineConfidence IntervalsHumansMulticenter Studies as TopicMedicineHepatitis B VaccinesVaccines CombinedAdverse effectDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicHepatitis B virusBooster (rocketry)ReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

The Oxidative Stress Concept of Nitrate Tolerance and the Antioxidant Properties of Hydralazine

2005

The hemodynamic and anti-ischemic effects of nitroglycerin (NTG) are rapidly blunted as a result of the development of nitrate tolerance. With initiation of NTG therapy, it is possible to detect neurohormonal activation and intravascular volume expansion. These so-called pseudotolerance mechanisms may compromise the vasodilatory effects of NTG. Long-term nitrate treatment also is associated with decreased vascular responsiveness caused by changes in intrinsic mechanisms of the tolerant vasculature itself. According to the oxidative stress concept, increased vascular superoxide (O 2 − ) production and an increased sensitivity to vasoconstrictors secondary to activation of protein kinase C co…

Malemedicine.medical_specialtyMaximum Tolerated Dosegenetic structuresDrug ResistanceMyocardial IschemiaPharmacologyCoronary Angiographymedicine.disease_causeSeverity of Illness IndexDrug Administration ScheduleNitric oxideNitroglycerinchemistry.chemical_compoundInternal medicinemedicineAnimalsHumansDrug Interactionschemistry.chemical_classificationClinical Trials as TopicReactive oxygen speciesDose-Response Relationship Drugbusiness.industryHydralazineHydralazineLong-Term Careeye diseasesDisease Models AnimalOxidative StresschemistryHeart Function TestsExercise TestCardiologyFemaleVascular ResistanceEndothelium Vascularsense organsSodium nitroprussideCardiology and Cardiovascular MedicineSoluble guanylyl cyclasebusinessNicotinamide adenine dinucleotide phosphatePeroxynitriteOxidative stressmedicine.drugThe American Journal of Cardiology
researchProduct

Mediterranean diet and heart rate: the PREDIMED randomised trial

2014

A higher heart rate (HR) has been associated with increased total and cardiovascular mortality [1] and [2]. Clinical trials support the beneficial effect of decreasing HR in patients with heart failure [3] and ischaemic heart disease [4]. A recent cross-sectional study showed that closer adherence to the Mediterranean diet (MeDiet) was related to lower HR [5]. We evaluated the association between adherence to the MeDiet (measured with a score from 0 to 14 obtained by a validated screener [6]) and HR using both a cross-sectional and a longitudinal analysis of the PREDIMED trial [7] and [8].

Malemedicine.medical_specialtyMediterranean dietHeart rateDiet MediterraneanDiabetes ComplicationsClinical trialsHeart RateMediterranean dietMedicineHumansSocioeconomicsAgedSistema cardiovascularAged 80 and overCorazónbusiness.industryMiddle AgedPredimedSurgeryClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesChristian ministryFemaleDietaCardiology and Cardiovascular MedicinebusinessOlive oil
researchProduct

Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis

2020

Recent publications showed that circulating neurofilaments (Nfs) may be used as a diagnostic biomarker distinguishing amyotrophic lateral sclerosis (ALS) from ALS mimics with high sensitivity and specificity.1–3 Furthermore, it has been shown that patients with higher Nf levels show faster disease progression1 and shorter survival.2 3 Nf levels remain rather stable during the course of disease.2 Current literature suggests that the diagnostic value of neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains in cerebrospinal fluid is about equal, whereas in blood NfL seems to be superior.4 In this study, we investigated the effect of a high-caloric fatty diet (HCFD) on …

Malemedicine.medical_specialtyNeurofilament[SDV]Life Sciences [q-bio]blood [Neurofilament Proteins]PlaceboDiet High-FatGastroenterology03 medical and health sciencesblood [Amyotrophic Lateral Sclerosis]0302 clinical medicineNeurofilament ProteinsInternal medicinePost-hoc analysismedicineHumansddc:610Amyotrophic lateral sclerosisMESH: Neurofilament ProteinsComputingMilieux_MISCELLANEOUSMESH: Amyotrophic Lateral SclerosisRandomized Controlled Trials as TopicMESH: HumansMESH: Middle Agedbusiness.industryTherapeutic effectAmyotrophic Lateral SclerosisMiddle Agedmedicine.diseaseMESH: Male3. Good healthRiluzole[SDV] Life Sciences [q-bio]Psychiatry and Mental healthMESH: Diet High-FatMESH: Randomized Controlled Trials as TopicTolerabilitystatistics & numerical data [Randomized Controlled Trials as Topic]motor neuron diseasePopulation studySurgeryFemaleNeurology (clinical)businessMESH: Female030217 neurology & neurosurgerymedicine.drug
researchProduct